National

Odds-defying Prostate Cancer Drug Developed In B.C. Hits Clinical Trials

Darpan News Desk, 02 Dec, 2015 02:02 PM

VANCOUVER — A made-in-British Columbia treatment is offering fresh hope to men battling prostate cancer.

Researchers at the B.C. Cancer Agency and the University of British Columbia have been approved to leave the lab with their odds-defying breakthrough drug and begin clinical trials.

B.C. Cancer Agency scientist Dr. Marianne Sadar says the statistical chances of reaching this milestone of are one in 1,000.

The new drug — dubbed EPI-506 — targets the end of a protein on prostate cancer cells to make them more vulnerable to hormones like testosterone.

While the effectiveness of earlier trial drugs that targeted the protein's front quickly waned, lab research indicates this new treatment successfully slows tumour growth past the early stages of treatment.

Phase I clinical trials begin today at sites across North America for the drug, which received $2.6 million from the B.C. Cancer Foundation over its 17-year development.

Prev Next

MORE National ARTICLES

B.C. Wife, Husband Stuck After IRA-Related Refugee Claim Turned Down

A former British soldier married to a disabled Canadian woman may be forced to leave their Victoria home for the United Kingdom after a series of missteps and a snarl of red tape.

B.C. Wife, Husband Stuck After IRA-Related Refugee Claim Turned Down

Grieving Family Of British Diver Says Inquest Could Improve Scuba Diving Safety In B.c.

The 27-year-old was swept away by the tidal current and his body was not found for more than seven weeks.

Grieving Family Of British Diver Says Inquest Could Improve Scuba Diving Safety In B.c.

Nearly One In Six Could Not Handle $500 Increase In Mortgage Payment: Poll

Another 26 per cent said they would be concerned, but could probably handle it.

Nearly One In Six Could Not Handle $500 Increase In Mortgage Payment: Poll

TPP: Will Canadian Companies Take Advantage Of The World's Largest Trade Zone?

With the world's largest economy right next door, Canada's business community has had good reason to remain focused on the fish-in-a-barrel opportunities offered by the United States market.